1. Aronson JK, Ferner RE. Biomarkers-a general review. Curr Protoc Pharmacol 2017; 76: 9.23.1-9.23.17.
2.
Navrazhina K, Garcet S, Gonzalez J, et al. In-depth analysis of the hidradenitis suppurativa serum proteome identifies distinct inflammatory subtypes. J Invest Dermatol 2021; 141: 2197-207.
3.
Wolk K, Wenzel J, Tsaousi A, et al. Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Br J Dermatol 2017; 177: 1385-93.
4.
Möller H, Ohlsson K, Linder C, et al. The flare-up reactions after systemic provocation in contact allergy to nickel and gold. Contact Dermatitis 1999; 40: 200-4.
5.
Serra R, Buffone G, Falcone D, et al. Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin. Wound Repair Regen 2013; 21: 395-401.
6.
Shao S, Cao T, Jin L, et al. Increased lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion. Invest Dermatol 2016; 136: 1418-28.
7.
Seo SJ, Ahn JY, Hong CK, et al. Expression of neutrophil gelatinase-associated lipocalin in skin epidermis. J Invest Dermatol 2006; 126: 510-2.
8.
Hau CS, Kanda N, Tada Y, et al. Lipocalin-2 exacerbates psoriasiform skin inflammation by augmenting T-helper 17 response. J Dermatol 2016; 43: 785-94.
9.
Ren K, Xia Y. Lipocalin 2 participates in the epidermal differentiation and inflammatory processes of psoriasis. J Inflamm Res 2022; 15: 2157-66.
10.
Visvanathan S, Baum P, Vinisko R, et al. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. J Allergy Clin Immunol 2019; 143: 2158-69.
11.
Hay RA, Samir N, Safwat M, et al. Tissue lipocalin-2 in psoriasis: is it a marker of metabolic disturbance or a possible marker of therapeutic efficacy after narrow band ultraviolet B? J Dermatolog Treat 2020; 31: 519-23.
12.
Frątczak A, Miziołek B, Łupicka-Słowik A, et al. Significance of neutrophil gelatinase-associated lipocalin (NGAL) and proprotein convertase subtilisin/kexin type 9 (PCSK9) for the monitoring of treatment response to cyclosporine in patients with psoriasis. Life (Basel) 2023; 13: 1873.
13.
Wolk K, Frambach Y, Jacobi A, et al. Increased levels of lipocalin 2 in palmoplantar pustular psoriasis. J Dermatol Sci 2018; 90: 68-74.
14.
Gul FC, Cicek D, Kaman D, et al. Changes of serum lipocalin-2 and retinol binding protein-4 levels in patients with psoriasis and Behçet’s disease. Eur J Dermatol 2015; 25: 195-7.
15.
Romaní J, Caixàs A, Ceperuelo-Mallafré V, et al. Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch Dermatol Res 2013; 305: 105-12.
16.
Kamata M, Tada Y, Tatsuta A, et al. Serum lipocalin-2 levels are increased in patients with psoriasis. Clin Exp Dermatol 2012; 37: 296-9.
17.
Ataseven A, Kesli R, Kurtipek GS, Ozturk P. Assessment of lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1, inter-leukin-6, homocysteine, and uric acid levels in patients with psoriasis. Dis Markers 2014; 2014: 541709.
18.
Aizawa N, Ishiuji Y, Tominaga M, et al. Relationship between the degrees of itch and serum lipocalin-2 levels in patients with psoriasis. J Immunol Res 2019; 2019: 8171373.
19.
Baran A, Świderska M, Myśliwiec H, Flisiak I. Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels. J Dermatolog Treat 2017; 28: 136-40.
20.
Colak S, Omma A, Sandikci SC, et al. Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis. Bratisl Lek Listy 2019; 120: 65-9.
21.
Sokolova MV, Simon D, Nas K, et al. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther 2020; 22: 26.
22.
El-Hadidi H, Samir N, Shaker OG, Otb S. Estimation of tissue and serum lipocalin-2 in psoriasis vulgaris and its relation to metabolic syndrome. Arch Dermatol Res 2014; 306: 239-45.
23.
Mallbris L, O’Brien KP, Hulthén A, et al. Neutrophil gelatinase-associated lipocalin is a marker for dysregulated keratinocyte differentiation in human skin. Exp Dermatol 2002; 11: 584-91.
24.
Lee JH, Kye KC, Seo EY, et al. Expression of neutrophil gelatinase-associated lipocalin in calcium-induced keratinocyte differentiation. J Korean Med Sci 2008; 23: 302-6.
25.
Hau CS, Kanda N, Tada Y, et al. Lipocalin-2 exacerbates psoriasiform skin inflammation by augmenting T-helper 17 response. J Dermatol 2016; 43: 785-94.
26.
Stisen ZR, Nielsen SM, Ditlev SB, et al. Treatment-related changes in serum neutrophil gelatinase-associated lipocalin (NGAL) in psoriatic arthritis: results from the PIPA cohort study. Scand J Rheumatol 2024; 53: 21-8.
27.
Dopytalska K, Sobolewski P, Błaszczak A, et al. Psoriasis in special localizations. Reumatologia 2018; 56: 392-8.
28.
Furutani K, Chen O, McGinnis A, et al. Novel proresolving lipid mediator mimetic 3-oxa-PD1n-3 docosapentaenoic acid reduces acute and chronic itch by modulating excitatory and inhibitory synaptic transmission and astroglial secretion of lipocalin-2 in mice. Pain 2023; 164: 1340-54.
29.
Bazid HAS, Sakr HG, Abdallah RA, et al. Serum and tissue lipocalin-2 expression in chronic kidney disease pruritic patients. Appl Immunohistochem Mol Morphol 2023; 31: 635-43.